Prometheus Laboratories Announces Collaboration with Celltrion for Anser Testing
Prometheus Laboratories Inc. ("Prometheus"), a leader in precision healthcare, today announced a collaboration with Celltrion USA, Inc. ("Celltrion USA") to validate and expand the upper limit of quantitation for Anser® IFX (infliximab) therapeutic drug monitoring (TDM) testing for patients receiving ZYMFENTRA® (infliximab-dyyb). ZYMFENTRA is the only FDA-approved subcutaneous infliximab (IFX) formulation for maintenance treatment in adults with...
Read more








